Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 363-369

  Salinas, Gregory D ^a   Robinson, Caroline O ^a   Abdolrasulnia, Maziar ^a  

^a CE Outcomes LLC   (United States)

Author keywords

Attitudes; Opioids; REMS; Survey

Indexed keywords

EXTENDED RELEASE OPIOID; LONG LASTING OPIOID; NARCOTIC ANALGESIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CERTIFICATION; CHRONIC PAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HUMAN; MALE; MEDICAL EDUCATION; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PROFESSIONAL COMPETENCE; REGISTER; RISK EVALUATION AND MITIGATION STRATEGIES; TREATMENT PLANNING; WORKLOAD;

EID: 84874992382     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S35798     Document Type: Article

References (14)

1. Lippe PM. The decade of pain control and research. Pain Med. 2000;1:286.
2. Gordon DB, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165:1574-1580.
3. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
4. American Pharmacists Association. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system. J Am Pharm Assoc. 2009;49:729-743.
5. Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011;7:109-115.
6. Salinas GD, Susalka D, Burton BS, et al. Risk assessment and counseling behaviors of healthcare professionals managing patients with chronic pain: a national multi-faceted assessment of physicians, pharmacists, and their patients. J Opioid Manag. 2012. In press.
7. US Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm111350.htm. Accessed December 2, 2011.
8. United States Centers for Medicare and Medicaid Services. EHR Incentive Programs. Available from: https://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/index.html?redirect=/EHRIncentivePrograms. Accessed June 12, 2012.
9. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94-101.
10. Busch SH, Frank RG, Leslie DL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv. 2010;61:11-16.
11. Hassanin H, Harbi A, Saif A, Davis J, Easa D, Harrigan R. Changes in antidepressant medications prescribing trends in children and adolescents in Hawai'i following the FDA black box warning. Hawaii Med J. 2010;69:17-19.
12. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2008;165:42-50.
13. Shatin D, Gardner JS, Stergachis A, Blough D, Graham D. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf. 2005;14:149-154.
14. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in "Dear doctor" letters and in black box labels. Clin Pharmacol Ther. 2002;72:735-742.